By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists agreed that while XLV has a fee advantage, its high concentration in a few mega-cap stocks, particularly Eli Lilly, exposes it to significant risk. The key debate centered around whether mid-cap biotech stocks could outperform in the next five years, triggering a sector rotation and making IYH's broader exposure more attractive.
Risk: Mega-cap concentration risk, particularly in Eli Lilly, exposes XLV to significant downside if the GLP-1 narrative cools or regulatory pricing pressure hits these specific leaders.
Opportunity: Potential outperformance of mid-cap biotech stocks, which could trigger a sector rotation and make IYH's broader exposure more attractive.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Choosing between the State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) and the iShares U.S. Healthcare ETF (NYSEMKT:IYH) often comes down to a preference for lower fees versus broader diversification.
Both funds provide concentrated exposure to the U.S. healthcare market, encompassing pharmaceutical giants and medical technology companies. While they share top holdings like Eli Lilly and Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), and AbbVie Inc. (NYSE:ABBV), differences in cost and market-cap concentration could significantly impact long-term results.
| Metric | IYH | XLV | |---|---|---| | Issuer | iShares | SPDR | | Expense ratio | 0.38% | 0.08% | | 1-yr return (as of June 8, 2026) | 15.30% | 15.60% | | Dividend yield | 1.20% | 1.70% | | Beta | 0.58 | 0.57 | | AUM | $3.2 billion | $39.2 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
The State Street Health Care Select Sector SPDR ETF is notably more affordable, with an expense ratio of 0.08% compared to the 0.38% charged by the iShares U.S. Healthcare ETF. For income-focused investors, XLV also offers a higher payout, providing more yield per dollar invested than IYH.
| Metric | IYH | XLV | |---|---|---| | Max drawdown (5 yr) | (17.90%) | (17.10%) | | Growth of $1,000 over 5 years (total return) | $1,273 | $1,342 |
The State Street Health Care Select Sector SPDR ETF (XLV) provides exposure to 60 healthcare companies specifically selected from the S&P 500. Its largest positions include Eli Lilly and Co. at 16.52%, Johnson & Johnson at 10.15%, and AbbVie Inc. at 7.15%. Launched in 1998, it has paid $2.51 per share over the trailing 12 months. Its portfolio is 100% weighted toward the healthcare sector and excludes smaller companies not found in the large-cap benchmark.
The iShares U.S. Healthcare ETF (IYH) holds a larger basket of 102 stocks, which may appeal to those seeking exposure to mid-cap companies alongside large-cap leaders. Its largest positions include Eli Lilly and Co. at 16.17%, Johnson & Johnson at 9.81%, and AbbVie Inc. at 6.94%. Launched in 2000, it has a trailing-12-month dividend of $0.81 per share. Like its counterpart, it maintains 100% exposure to the healthcare sector but offers slightly broader diversification across market capitalizations.
For more guidance on ETF investing, check out the full guide at this link.
The State Street Health Care Select Sector SPDR ETF (XLV) and the iShares U.S. Healthcare ETF (IYH) are both viable choices for those who are seeking exposure to the U.S. healthcare sector. Let’s see how these exchange-traded funds (ETFs) compare to one another.
First, there’s XLV. This fund has a history stretching back nearly 30 years, to 1998, making it one of the first sector-focused ETFs. Over its long history, the fund has performed well. Its 812% return over its lifetime equates to a compound annual growth rate (CAGR) of 8.4%. The benchmark S&P 500, by comparison, has generated a total return of 907% and a CAGR of 8.8% over this same period. In other words, the XLV has slightly underperformed the market over its lifetime — but not by much. In addition, there were long stretches during which XLV outperformed.
At any rate, XLV offers investors wide exposure to the healthcare sector at an affordable price; the fund’s expense ratio is only 0.08%. As for income, the fund has a respectable dividend yield of 1.6%.
Turning to IYH, this fund has a similarly long history, having been started in 2000. Over its lifetime, the fund has generated a total return of 596%, equating to a CAGR of 7.7%. However, the S&P 500 has delivered better returns, with a 728% total return and an 8.5% CAGR over the same period.
As for fees, IYH has higher fees compared to XLV, with an expense ratio of 0.38%. Its dividend yield, meanwhile, is lower at 1.3%.
In summary, many investors, particularly buy-and-hold investors, may favor XLV due to its lower fees, higher dividend yield, and superior historical performance.
Before you buy stock in Select Sector SPDR Trust - State Street Health Care Select Sector SPDR ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Select Sector SPDR Trust - State Street Health Care Select Sector SPDR ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $440,440! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,303,950!
Now, it’s worth noting Stock Advisor’s total average return is 956% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 16, 2026. *
Jake Lerch has positions in Select Sector SPDR Trust - State Street Health Care Select Sector SPDR ETF. The Motley Fool has positions in and recommends AbbVie and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Both XLV and IYH function more as concentrated bets on a few GLP-1 leaders rather than true diversified healthcare sector vehicles."
The article frames this as a simple choice between fees and diversification, but it misses the elephant in the room: index concentration risk. With Eli Lilly alone representing over 16% of both XLV and IYH, investors aren't buying a 'healthcare sector' basket; they are buying a leveraged bet on GLP-1 weight-loss drugs. XLV’s 0.08% expense ratio is attractive, but it forces a passive, high-beta exposure to a handful of mega-caps. If the GLP-1 narrative cools or regulatory pricing pressure hits these specific leaders, the 'diversification' offered by IYH’s extra 42 stocks is negligible because the top-heavy weighting remains largely identical. Investors should look at equal-weighted alternatives if they actually want sector-wide exposure.
The concentration in LLY, JNJ, and ABBV is actually a feature, not a bug, as these companies possess the pricing power and R&D moats necessary to outperform in a high-interest-rate environment.
"XLV wins on fees and yield for passive holders, but both funds are overweight LLY/JNJ at stretched valuations, making the choice between them less important than whether to own healthcare sector exposure at all right now."
XLV's 30bps fee advantage over IYH compounds meaningfully over decades—on a $100k position, that's ~$300/year saved initially, growing as AUM compounds. The 1.70% yield and near-identical 5-year performance (1.342x vs 1.273x) make the fee case airtight for buy-and-hold investors. However, the article conflates 'lower fees' with 'better buy' without addressing sector timing: healthcare has massively outperformed (LLY up 2x in 18 months), and both funds are now concentrated bets on mega-cap pharma at peak valuations. The article's 0.57-0.58 beta claims seem understated given LLY's 2.5x volatility.
XLV's 60-stock concentration on S&P 500 healthcare only—excluding mid-cap innovators in medtech or biotech—may underperform IYH's 102-stock basket if smaller-cap healthcare outperforms in a rotation away from mega-cap pharma. Fee savings evaporate if IYH's broader exposure captures the next wave.
"XLV's fee and yield edge is real but its greater concentration in mega-cap pharma names creates unexamined downside risk the article glosses over."
The article positions XLV as superior to IYH on fees (0.08% vs 0.38%), yield (1.70% vs 1.20%), and 5-year returns ($1,342 vs $1,273 growth), citing its S&P 500 large-cap focus. Yet both delivered nearly identical 1-year returns and betas around 0.57-0.58, while XLV's heavier 16.5% Eli Lilly weighting and 60-stock concentration introduce single-name risk not offset by the 0.30% fee savings alone. Lifetime CAGRs show both trailed the S&P 500, suggesting sector allocation itself may be the larger driver than ETF choice.
Lower ongoing fees compound to meaningful alpha over decades for buy-and-hold investors, and XLV's $39B AUM provides tighter tracking and liquidity that IYH's broader 102 holdings cannot match during stress periods.
"XLV offers a compelling core exposure due to ultra-low fees and higher yield, but its concentration and regulatory risk could cap upside."
XLV’s 0.08% expense and 1.70% dividend yield look compelling next to IYH’s 0.38% and 1.20%, supporting higher cash-on-cash returns for a core healthcare position. Yet XLV’s 60-name, large-cap tilt concentrates risk in a few stocks (Lilly, J&J, AbbVie). A policy shift on drug pricing or patent cliffs for Humira, plus ongoing litigation risk, could hit the top holdings hard, with less offset from mid-cap innovators. Also, the narrower basket may miss growth outside big pharma and devices that broader funds could capture. In sum, the cost edge is real, but concentration and policy risk temper the upside.
Con: The concentration XLV inherits could backfire in a policy shock or a stock-specific miss. A broader healthcare ETF might weather idiosyncratic hits better and capture growth XLV misses.
"ETF liquidity is irrelevant for large-cap healthcare; the real risk is missing out on mid-cap innovation due to index concentration."
Grok, you mention XLV's $39B AUM provides 'tighter tracking,' but that is a red herring in a sector-specific play. Liquidity in names like LLY or JNJ is so deep that the spread difference between XLV and IYH is negligible for retail. The real risk is the 'mega-cap trap' Gemini identified. If we see a rotation into small-cap biotech, the tracking error won't be the problem; the lack of exposure to innovation will be.
"Policy risk is symmetric between funds; the real bet is mid-cap biotech outperformance, which neither fund captures well."
Claude and ChatGPT both flag policy risk on drug pricing, but neither quantifies it. Humira's patent cliff hits 2023—already priced in. GLP-1 pricing pressure is real, but CMS negotiation affects *all* mega-cap pharma equally. XLV and IYH both absorb that hit identically. The differentiation isn't policy exposure; it's whether you believe mid-cap biotech outperforms in the next 5 years. That's a sector rotation bet, not an XLV-vs-IYH choice. Fee math still favors XLV unless you're timing a specific rotation.
"XLV's concentration makes it more vulnerable to policy shocks than Claude acknowledges, eroding its fee advantage."
Claude assumes policy hits like GLP-1 pricing caps affect both ETFs the same, yet XLV's heavier Lilly concentration amplifies downside versus IYH's broader holdings. Fee savings of 30bps won't offset amplified drawdowns if mega-cap pharma faces binding negotiations. The mid-cap outperformance scenario Claude dismisses could actually be triggered by the very policy shifts that punish XLV more severely.
"XLV's mega-cap concentration creates tail risk that fee savings can't offset in policy-driven shocks; broader diversification in IYH matters for downside protection."
Grok, you overemphasize the tracking tightness and fee delta while downplaying the mega-cap concentration risk. XLV's Lilly tilt isn't just a single-name hit risk—it's a lever for policy-shock (speculative), patent-pricing (speculative), and litigation outcomes to move the ETF more than IYH, especially in a rotation toward mid-caps. The 0.08% vs 0.38% fee gap won't save you in a tail risk scenario; diversification matters in downside protection.
The panelists agreed that while XLV has a fee advantage, its high concentration in a few mega-cap stocks, particularly Eli Lilly, exposes it to significant risk. The key debate centered around whether mid-cap biotech stocks could outperform in the next five years, triggering a sector rotation and making IYH's broader exposure more attractive.
Potential outperformance of mid-cap biotech stocks, which could trigger a sector rotation and make IYH's broader exposure more attractive.
Mega-cap concentration risk, particularly in Eli Lilly, exposes XLV to significant downside if the GLP-1 narrative cools or regulatory pricing pressure hits these specific leaders.